Parenteral caffeine products for veterinary emergency use are manufactured as sterile caffeine citrate solutions rather than solutions of anhydrous caffeine base. The solubility of caffeine base in water at 25°C is approximately 1 g in 46 mL, while caffeine citrate dissolves at approximately 1 g in 4 mL under the same conditions. This difference determines the injectable formulation route. A standard compounding batch using caffeine veterinary grade API as the source base is converted to caffeine citrate by reaction with citric acid monohydrate in Water for Injection, targeting a final concentration of 20 mg/mL caffeine citrate, equivalent to 10 mg/mL caffeine base. The solution is prepared in a stainless-steel jacketed vessel at 20–25°C and mixed at 200–400 rpm until dissolution is complete. pH is adjusted from 4.5 to 5.5 with 0.1 N citric acid or sodium hydroxide. Sodium chloride may be added to achieve an osmolality of 290–310 mOsm/kg. Sterile filtration is carried out through a 0.22 µm PVDF or polyethersulfone membrane under ISO 14644-1 Class 5 laminar airflow. The filtered solution is filled into Type I borosilicate glass vials of 2 mL or 5 mL nominal volume, under nitrogen overlay if headspace oxygen exceeds 2.0% v/v. Terminal sterilization is then performed at 121°C for 15 minutes. Finished units are tested for sterility according to USP <71>, bacterial endotoxins according to USP <85> with an acceptance limit of less than 2.0 EU/mL for a 2 mL dose, and particulate matter according to USP <788>. Assay of caffeine base is determined by high-performance liquid chromatography with UV detection at 272 nm; the acceptance range is 98.0–102.0% of label claim. The terminal product is a single-dose sterile injection for use in veterinary emergency settings where a parenteral respiratory stimulant is clinically indicated. Because published data for this specific veterinary configuration are limited, stability and compatibility studies follow VICH GL3 and should include degradation products theophylline and 1,7-dimethylxanthine.

Why Oral Solutions Select Caffeine Citrate Over Anhydrous Base

Non-sterile oral solutions for veterinary administration via oral syringe or nasogastric tube use caffeine citrate to avoid the slow dissolution and recrystallization of caffeine base. A 20 mg/mL caffeine citrate solution delivers 10 mg/mL caffeine base and remains clear at 2–8°C for the distribution chain. Anhydrous caffeine solutions of the same base concentration require heating or co-solvents that are unsuitable for neonatal patients. A preservative system is selected according to the target species: methylparaben at 0.10–0.18% w/v and propylparaben at 0.02–0.05% w/v are typical for oral aqueous vehicles, but benzyl alcohol is excluded from formulations intended for animals less than 7 days of age because of metabolic immaturity. Glycerin at 15–25% v/v may be included as a palatability and viscosity modifier, and citric acid buffer maintains pH in the range of 3.2–4.0. Processing uses purified water at 25°C, not exceeding 40°C to minimize preservative degradation. The API is added under continuous mixing at 150–300 rpm in a stainless-steel tank; the batch is filtered through a 0.45 µm clarification filter. Filling into amber polyethylene terephthalate bottles with low-density polyethylene dropper inserts is performed at a fill volume tolerance of ± 2.0%. The finished oral solution is tested for microbial enumeration according to USP <61> with total aerobic microbial count below 10² CFU/mL and total combined yeasts and molds below 10¹ CFU/mL. Assay by HPLC at 272 nm is controlled at 95.0–105.0% of label claim. The terminal product is stored at controlled room temperature, protected from light, and used mainly in veterinary hospitals and field research; it is not a licensed product in all jurisdictions.

Tablet Compression Profiles Without Binder Solutions

Tablet dosage forms for caffeine in companion animal pharmacokinetic work are manufactured by direct compression because aqueous wet granulation induces caffeine migration during drying. The anhydrous veterinary grade API is milled to a particle size distribution with d90 less than 75 µm before blending. A representative direct compression formula for a 10 mg tablet is as follows: caffeine 10.0 mg, microcrystalline cellulose PH102 48–55 mg, lactose monohydrate 25–30 mg, crospovidone 2.0–3.0 mg, colloidal silicon dioxide 0.5–1.0 mg, and magnesium stearate 0.6–1.0 mg. Blending is performed in a bin blender at 60–70% of nominal capacity for 15 minutes at 15 rpm before lubricant addition, then an additional 3 minutes after magnesium stearate loading. The blend is compressed on a rotary tablet press equipped with 10 mm round flat-faced bevel-edge punches. Target tablet hardness is 70–100 N measured according to USP <1216>, with friability below 1.0% after 100 rotations. Disintegration in 0.1 N hydrochloric acid at 37°C should occur within 15 minutes as judged by USP <701>. Dissolution is performed by USP <711> Apparatus 2 at 50 rpm in 900 mL of 0.1 N hydrochloric acid at 37°C; because caffeine is highly soluble, the acceptance criterion is typically not less than 80% dissolved in 30 minutes. Tablets are dedusted and packed in aluminum-PVC/PVDC blisters or high-density polyethylene bottles with desiccant. The finished product is intended for controlled oral studies only; batch records include residual solvent testing according to VICH GL18 for any solvents used during milling or granulation, although this direct compression route avoids binders and solvents.

Encapsulation lines handling caffeine at 20–50 mg per capsule use a preprocessed grade with particle size d90 ≤ 75 µm to maintain weight and content uniformity. A powder blend for hard gelatin or hypromellose capsules consists of caffeine base, lactose monohydrate, microcrystalline cellulose PH101, pregelatinized starch, and 0.5–1.0% magnesium stearate. The blend is passed through a 30 mesh screen before encapsulation to break soft agglomerates. Capsule filling is performed on an intermittent-motion dosator or tamping-pin encapsulation machine operating at 60–75% of maximum speed; fill weight is monitored every 15 minutes with individual capsule weight variation controlled to USP <905> acceptance values for 10 to 149 mg net fill. The two formulation-specific risks are moisture uptake and electrostatic charge. Anhydrous caffeine converts to the monohydrate when exposed to relative humidity above 60%; therefore, the processing suite is maintained at 18–25°C and 40–55% RH, and bulk hold time between blending and encapsulation is limited to 8 hours. If the Carr index of the blend exceeds 25, colloidal silicon dioxide is increased in 0.25% increments until flowability reaches an angle of repose of 30–35°. Dissolution testing follows USP <711> with Apparatus 2 at 50 rpm in 0.1 N hydrochloric acid; capsules should release not less than 80% of label claim within 30 minutes. Finished capsules are packed in polyvinyl chloride/polyethylene/polyvinylidene chloride blister cavities with aluminum lidding, with a desiccant if the closure moisture vapour transmission rate exceeds 0.5 mg/day. The terminal product is for investigational single-dose oral administration in target species; stability batches are placed at 25°C/60% RH long-term and 40°C/75% RH accelerated conditions according to VICH GL3.

Dry Powder Blending Limits in Twin-Shell Mixers

Bulk oral powders for reconstitution or top-dress administration require geometric dilution of caffeine into a soluble carrier such as lactose monohydrate or dextrose before machine blending. A target blend concentration of 10 mg/g caffeine base is manufactured by first triturating caffeine with an equal mass of carrier through a 40 mesh screen, then increasing the mass in successive proportions until a 5 kg batch is achieved. The blender is a twin-shell V-type unit operated at 65–75% of rated capacity for 20 minutes at 15 rpm. Blend uniformity is assessed by sampling 10 locations with a thief probe; HPLC analysis at 272 nm must give a relative standard deviation of ≤ 5.0% and individual values within 90.0–110.0% of label claim, consistent with USP <905> principles. Powder flow for sachet filling is characterised by angle of repose not exceeding 40° and compressibility index not exceeding 25; if these thresholds are exceeded, 0.5–1.0% colloidal silicon dioxide is added. Filling into foil-lined sachets is performed at a target fill weight tolerance of ± 5.0% and seal integrity is checked by vacuum leak testing. The finished powder is non-sterile and must meet USP <61> microbial limits; total aerobic microbial count is less than 10³ CFU/g, and total combined yeasts and molds less than 10² CFU/g. The terminal product is reconstituted with water immediately before oral administration. Storage of bulk powder at 15–25°C and ≤ 60% RH prevents caking; any batch exposed to RH above 60% for more than 24 hours is quarantined and re-assayed for water content and caffeine base potency.

When Granulation Becomes Necessary for Low-Dose Uniformity

Granulation of caffeine into an intermediate particle size of 150–500 µm is used when direct powder blends segregate during long-distance transfer or when dust generation exceeds 5 mg/m³ when measured by a handheld aerosol monitor in the filling suite. Wet granulation is executed with a povidone K-30 binder solution at 3–5% w/w in purified water. Caffeine, lactose monohydrate, and maize starch are preblended in a high-shear granulator at an impeller speed of 200–300 rpm and a chopper speed of 1500–2000 rpm for 5 minutes. Binder solution is added over 2–4 minutes at a spray rate of 50–80 g/min for a 5 kg batch. The wet mass is sieved through an 0.8 mm screen and dried in a fluid-bed dryer at an inlet air temperature of 50–60°C until loss on drying is 1.5–2.5%. Dried granules are sized through a 600 µm screen and blended with crospovidone and sodium stearyl fumarate as extragranular disintegrant and lubricant. Granule particle size is measured according to USP <786> by analytical sieving; the proportion below 150 µm is maintained below 20% to avoid residual dust. Friability of granules is measured by a vibrating sieve test rather than tablet friability; material passing a 75 µm screen after 10 minutes of vibration should not exceed 5.0% of batch mass. The finished granules are filled into unit-dose sachets or bulk polyethylene bags with a fill weight tolerance of ± 3.0%. The terminal product can be sprinkled on a small amount of feed or reconstituted in water at a concentration of 5 mg/mL caffeine base. Because caffeine granules may contain residual moisture below 2.5%, the chemical stability at 40°C/75% RH is tested over 6 months under VICH GL3 protocols.

Caffeine-containing premixes for research diets are manufactured as dry concentrates that contain caffeine base uniformly distributed onto a feed-compatible carrier such as calcium carbonate, ground corn, or maltodextrin. This segment is not equivalent to a licensed medicated feed additive, and inclusion in diets for food-producing animals is not acceptable in jurisdictions without a specific maximum residue limit and marketing authorisation. A typical research premix contains 1.0–5.0% w/w caffeine base. The manufacturing sequence begins by passing the carrier through an 18 mesh screen to remove foreign material; then caffeine is loaded in layers into a horizontal ribbon mixer at 70–80% of rated capacity. Mixing is performed for 20 minutes at 25 rpm, with a validated dead-spot mapping using a high-intensity tracer to identify zones requiring baffle adjustment. After mixing, samples are collected from 10 positions, including the discharge gate, and analysed by HPLC at 272 nm. The coefficient of variation for caffeine concentration must be less than 5.0% across the batch. The premix is discharged into polyethylene-lined multi-wall paper bags of 25 kg with a heat-sealed moisture barrier. Moisture content is controlled to less than 5.0% by Karl Fischer titration; exposure to RH above 65% causes caffeine redistribution and carrier particle aggregation. The terminal premix is used exclusively in experimental feeding programs under animal welfare protocols; each bag is labelled with the batch potency, storage condition, and the statement “not for food-producing animals unless authorised.” Shipping is performed in sealed containers at 15–25°C, and retained samples are tested for caffeine assay according to USP <905> or equivalent validated HPLC procedures.

When Research Protocols Require Steady-State Caffeine Intake in Rodents

Long-term rodent studies frequently administer caffeine through drinking water, and the bulk solution for this application is prepared from caffeine citrate or a dilute solution of caffeine base after pH adjustment. A 10× stock solution is manufactured at 1.0–5.0 mg/mL caffeine base equivalent using purified water at 20–25°C; sodium benzoate at 0.1% w/v may be added as a preservative if the solution will be used beyond 24 hours. The solution is filled into amber polycarbonate carboys to protect caffeine from ultraviolet degradation. The terminal working solution is prepared by dilution into animal facility drinking water to a final concentration commonly between 0.05 and 0.5 mg/mL caffeine base, depending on the study protocol. Water intake is monitored gravimetrically; bottles are replaced every 48–72 hours, and residual caffeine is measured by HPLC at 272 nm in retained samples to verify stability. The microbiological limit for this non-sterile solution follows USP <61> with total aerobic microbial count below 10² CFU/mL at the point of use. The use of caffeine in drinking water is appropriate only for research species such as mice and rats under an Institutional Animal Care and Use Committee protocol; it is not formulated as a therapeutic drinking water product for production animals. Because caffeine is bitter, palatability can be a confounding factor at concentrations above 0.3 mg/mL; sodium cyclamate or saccharin may be added in research formulations at 0.05–0.20% w/v if the protocol permits non-nutritive sweeteners.